MyFinsight
Home
Blog
About
First Tracks Biotherapeutics, Inc. (TRAX)
First Tracks Biotherapeutics, Inc. (TRAX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$80,451K
Free Cash flow
-$31,943K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Issuance of common stock in conn...
Proceeds from former parent comp...
Proceeds from public offerings
Others
Negative Cash Flow Breakdown
Net parent investment
Net loss
Prepaid expenses and other asset...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
Net loss
-33,374
-50,484
Depreciation and amortization
105
125
Stock-based compensation
8,319
11,503
Accretion/amortization of investments, net
-146
8
Amortization of right-of-use assets - operating
102
0
Prepaid expenses and other assets
12,359
-2,157
Accounts payable and other liabilities
5,236
4,146
Operating lease liabilities
-93
0
Net cash used in operating activities
-31,918
-32,561
Purchase of investments
0
0
Sales and maturities of investments
0
35,000
Purchases of property and equipment
25
17
Net cash provided by investing activities
-25
34,983
Issuance of common stock in connection with the spin-off
109,243
-
Proceeds from public offerings
75,200
-
Proceeds from the issuance of common stock upon the exercise of stock options
2,122
-
Proceeds from former parent company with spin-off
100,000
-
Payments for offering costs
26
-
Net parent investment
335,047
-7,851
Net cash provided by (used in) financing activities
-48,508
7,851
Net increase (decrease) in cash and cash equivalents
-80,451
10,273
Cash and cash equivalents, beginning of period
248,469
238,196
Cash and cash equivalents, end of period
168,018
248,469
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase
(decrease) in cash and cash...
-$80,451K
Issuance of common stock
in connection with...
$109,243K
Proceeds from former
parent company with...
$100,000K
Proceeds from public
offerings
$75,200K
Proceeds from the
issuance of common stock...
$2,122K
Stock-based compensation
$8,319K
Accounts payable and
other liabilities
$5,236K
Accretion/amortization of investments,
net
-$146K
Depreciation and
amortization
$105K
Amortization of right-of-use
assets - operating
$102K
Net cash provided by
(used in) financing...
-$48,508K
Net cash used in
operating activities
-$31,918K
Net cash provided by
investing activities
-$25K
Canceled cashflow
$286,565K
Canceled cashflow
$13,908K
Net parent
investment
$335,047K
Net loss
-$33,374K
Purchases of property and
equipment
$25K
Payments for offering
costs
$26K
Prepaid expenses and
other assets
$12,359K
Operating lease
liabilities
-$93K
Buy us a coffee